a developer of small molecule therapies for the treatment of cancer
Industry Biotechnology
A.I.dvisor tells us that EXEL and RIGL have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EXEL and RIGL's prices will move in lockstep.
Ticker / NAME | Correlation To EXEL | 1D Price Change % | ||
---|---|---|---|---|
EXEL | 100% | -0.40% | ||
RIGL - EXEL | 29% Poorly correlated | +0.18% | ||
RVMD - EXEL | 28% Poorly correlated | -1.31% | ||
ALGS - EXEL | 27% Poorly correlated | -0.61% | ||
RARE - EXEL | 27% Poorly correlated | -2.20% | ||
PLX - EXEL | 27% Poorly correlated | +13.71% | ||
More |
Ticker / NAME | Correlation To EXEL | 1D Price Change % |
---|---|---|
EXEL | 100% | -0.40% |
modules theme (9 stocks) | 25% Poorly correlated | -3.68% |
cancer theme (82 stocks) | 24% Poorly correlated | -5.37% |
drugs theme (254 stocks) | 23% Poorly correlated | -4.03% |
treatment theme (56 stocks) | 17% Poorly correlated | -4.29% |
biotechnology theme (238 stocks) | 16% Poorly correlated | -4.32% |